Pharmacally
Deramiocel
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Deramiocel
Health TidingsCapricor Reports 76% Slower Upper Limb Decline After Deramiocel Switch in HOPE-3 ExtensionCapricor Therapeutics reported HOPE-3 open-label extension data showing a 76% slower rate of upper limb function decline after patients with Duchenne muscular dystrophy switched from placebo to deramiocel.Fact-Checked
Health TidingsFDA Extends Deramiocel Review to November 2026 as Capricor Refines DMD IndicationThe FDA extended its review of Capricor’s investigational deramiocel to November 22, 2026, allowing additional time to assess new Phase 3 HOPE-3 data supporting a refined indication focused…Fact-Checked
Health TidingsFDA Schedules Advisory Committee Review of Deramiocel BLA for DMDCapricor Therapeutics has reached a key regulatory milestone as the FDA scheduled a July 29 advisory committee meeting to review the Biologics License Application for deramiocel, its allogeneic…Fact-Checked
Health TidingsCapricor Files Lawsuit Against NS Pharma Over Deramiocel AccessCapricor Therapeutics filed a lawsuit on May 7, 2026, in New Jersey Superior Court against Nippon Shinyaku and NS Pharma, claiming the deramiocel commercialization agreement’s pricing mechanism restricts…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.